Investing Profile

Michael Gladstone

VCInvestor
Partner at Atlas Venture
Photo of Michael Gladstone, Partner at Atlas Venture

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Harvard University Network
402 CONNECTIONS
L.E.K. Consulting Network
19 CONNECTIONS
Atlas Venture Network
12 CONNECTIONS
Atlas Venture Network
12 CONNECTIONS
Atlas Venture Network
12 CONNECTIONS
cb
$10.0M - $50.0M
$25.0M
14
CompanyStageDateRound SizeTotal Raised
Diagonal Therapeutics
Series BJan 2026$130M
Series AApr 2024$130M
$250M
Co-investors: Paulina Hill (Polaris Partners), James N. Topper (Frazier Healthcare Partners), Jernej Godec (Atlas Venture)
Pheon Therapeutics
Series BMay 2024$120M
Series ASep 2022$68M
$190M
Co-investors: Rogier Rooswinkel (Forbion)
SAPI
UndisclosedMar 2023
Co-investors: Nadav Ben-Chanoch (Pareto Holdings), Jon Oringer (Shutterstock), Edward Lando (Biowear)
Versanis Bio
Series AAug 2021$70M
$70M
Co-investors: Joe Jimenez (Aditum Bio)
Day One Biopharmaceuticals
Series BFeb 2021$130M
Series AMay 2020$60M
$190M
Co-investors: Julie Grant (Canaan Partners), Derek DiRocco (RA Capital)
Third Harmonic Bio
Series AJan 2019$50M
$50M
Co-investors: David Bonita (OrbiMed), Jason Rhodes (Atlas Venture)
Spero Therapeutics
Series BFeb 2016$30M
Series AJun 2015$30M
Series AApr 2014$3M
SeedDec 2013
$120M
Co-investors: Krishna Yeshwant (GV (Google Ventures)), Jean-François Formela (Atlas Venture), Vikas Goyal (SR One)
Surface Oncology
Series AJan 2015$35M
$35M
Co-investors: Elliott Sigal
Partner Atlas Venture2020 - Present
Principal Atlas Venture2015 - Present
Associate Atlas Venture2012 - 2014
Senior Associate Consultant L.E.K. Consulting2009 - 2012
MLSC Fellow Eutropics Pharmaceuticals2009 - 2009
Harvard University BA Biochemical Sciences